| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Exelixis, Inc. (EXEL) has 10 insiders with recent SEC Form 4 filings, including 0 buys and 19 sells. EXEL is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 1.96M | $104.92M | - | |
| Dir | 1.55M | $82.94M | - | |
| Dir | 1.19M | $63.50M | - | |
| CFO | 1.12M | $59.66M | - | |
| VP | 594.7K | $31.76M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 15, 2017 | Feldbaum Carl B47 | Director | Sale+OE | 32,988 | $21.58 | $711,830.92 | -28.3% | |
| May 10, 2017 | Morrissey Michael | President And CEO | Sale+OE | 211,300 | $21.87 | $4,622,159.38 | -46.8% | |
| May 5, 2017 | Morrissey Michael | President And CEO | Sale+OE | 259,149 | $22.24 | $5,762,838.02 | -46.3% | |
| May 1, 2017 | Schwab Gisela67 | Pres Prod Dev &Med Aff &CMO | Sale+OE | 89,910 | $23.01 | $2,068,519.00 | -20.8% | |
| Apr 3, 2017 | Marchesi Vincent T | Director | Sale+OE | 10,000 | $21.30 | $213,000.00 | -7.7% | |
| Mar 31, 2017 | Wyszomierski Jack L | Director | Sale+OE | 5,150 | $21.57 | $111,085.50 | -6.6% | |
| Mar 27, 2017 | Hessekiel Jeffrey54 | EVP And General Counsel | Sell | 6,884 | $21.02 | $144,701.68 | -2.5% | |
| Mar 22, 2017 | Hessekiel Jeffrey54 | EVP And General Counsel | Sale+OE | 23,787 | $20.54 | $488,584.98 | -7.9% | |
| Mar 20, 2017 | Papadopoulos Stelios53 | Director | Sale+OE | 10,000 | $21.66 | $216,600.00 | -0.8% | |
| Mar 20, 2017 | Feldbaum Carl B47 | Director | Sale+OE | 10,000 | $21.77 | $217,700.00 | -17.0% |